Arrowhead to Present at Upcoming Conferences
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that the
company will present at the following upcoming investor and scientific
conferences.
IBC’s 17th Annual TIDES Conference – San
Diego, May 3-6, 2015
May 5, 4:45 p.m. PDT – Christine Wooddell, Ph.D., group leader
will deliver an oral presentation titled, “A Hepatocyte-Targeted RNAi
Therapeutic for Alpha-1-Antitrypsin Deficiency-Associated Liver Disease”
May 6, 12:15 p.m. PDT – David Lewis, Ph.D., chief scientific
officer will deliver an oral presentation titled, “A Targeted
siRNA-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus
Infection”
Deutsche Bank 40th Annual Health Care Conference – Boston, May
6-7, 2015
May 7, 2:50 p.m. EDT – Bruce Given, M.D., chief operating officer
will make a corporate presentation
A live webcast of the presentation from the Deutsche Bank conference can
be accessed by visiting the Events section of the company’s website at http://ir.arrowheadresearch.com/events.cfm.
A replay will also be archived on the website.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate™ delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic
hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, actions of the U.S. Food and Drug Administration (FDA) and
similar global regulatory bodies, rapid technological change in our
markets, challenges to the validity of our intellectual property rights,
and the enforcement of our intellectual property rights. Arrowhead
Research Corporation’s most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q discuss some of the important
risk factors that may affect our business, results of operations and
financial condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Research Corporation
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Todd James
646-378-2926
ir@arrowres.com
or
Media:
Russo
Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media